Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Invest In Growth? - simplywall.st
21 hours ago • Google News
ArriVent BioPharma, Inc. Common Stock (AVBP)
US$ 21.870.28%
Price Chart
Key Statistics
Market Cap
$ 713.67M
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
156.11K
52W High
$ 36.37
52W Low
$ 15.47
Dividend Yield
0.00%
Beta
0.00
Technicals
50-Day MA
19.4777
200-Day MA
24.8946
52 Week High
36.37
52 Week Low
15.47
About AVBP
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancer.
Employees
52
Headquarters
Newtown Square, PA
CEO
Dr. Zhengbin Yao Ph.D.
Latest News
ArriVent BioPharma (AVBP) Coverage Initiated with 'Buy' Rating | - GuruFocus
Yesterday • Google News
Is ArriVent BioPharma (NASDAQ:AVBP) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
1 weeks ago • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg